Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Pfizer

Revenues down 3% in the quarter, up 8% for the year

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer

4Q Revenues: $13.6 billion (-3%)

4Q Earnings: $775 million (loss of $172 million 4Q15)

FY Revenues: $52.8 billion (+8%)

FY Earnings: $7.2 billion (+4%)

Comments: Innovative Health sales were $29.2 billion for the year, up 9%. Essential health sales were $23.6 billion, up 7%. Lyrica sales were $4.2 billion, up 14% for the year. Viagra sales were $1.2 billion, down 9%. Chantix sales were $842 million, up 26%. Loss of exclusivity for Prevnar 13 Adult impacted sales in the U.S., down 8% to $5.7 billion. Ibrance sales were $2.1 billion, up from $723 million FY15. Sutent sales were $1.1 billion, down 2%. Enbrel sales were down 13% to $2.9 billion. Xeljanz sales were up 77% to $927 million. Lipitor sales were $1.8 billion, down 6%. Premarin sales were flat at $1.0 billion. R&D expenses were $7.9 billion, up 2%. Financial results reflect legacy Hospira global operations, as well as the June 2016 acquisition Anacor Pharmaceuticals, which reflects three and six months of legacy operations.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters